[O-34] Oral Session 34
Clinical trial and Regenerative medicine 2 E

[O-34-9] Efficacy and Safety of satralizumab add-on therapy in a Phase 3 study in patients with NMOSD

^○Takashi Yamamura¹, Ingo Kleiter², Kazuo Fujihara³, Jacqueline Palace⁴, Benjamin Greenberg⁵, Beata Zakrzewska-pniewska⁶, Francesco Patti⁷, Albert Saiz⁸, Masayuki Haramura⁹, Yusuke Terada⁹, Yuichi Kawata⁹, Jerome De Seze¹⁰ (1.Department of Immunology, National Institute of Neuroscience, and the Multiple Sclerosis Center, National Center of Neurology and Psychiatry, Japan, 2.Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, and Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, 3.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, and the Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, 4.Department of Clinical Neurology, John Radcliffe Hospital, 5.Department of Neurology, University of Texas Southwestern Medical Center, 6.Department of Neurology, Warsaw Medical University, 7.Department G.F. Ingrassia, Neuroscience Section, University of Catania, 8.Service of Neurology, Hospital Clinic and Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, 9.Chugai Pharmaceutical, 10.Department of Neurology, Hôpital de Hautepierre, Clinical Investigation Center, INSERM)